NCT06824701 2025-12-03
TARZAN
University of Utah
Phase 1 Recruiting
Clinical Trials
13 trialsNCT04464798 2025-04-29
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Celgene
Phase 1 Terminated
NCT04136756 2023-06-15
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Nektar Therapeutics
Phase 1 Completed
NCT03189836 2021-10-11
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Cogent Biosciences, Inc.
Phase 1 Terminated
NCT02187133 2021-04-23
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT04361409 2020-04-28
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
China Medical University Hospital
Phase 1 Completed
NCT02776813 2020-03-31
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma
Cogent Biosciences, Inc.
Phase 1 Completed
NCT04279938 2020-02-21
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Royal Marsden NHS Foundation Trust
Phase 1 Withdrawn
NCT01729104 2019-10-22
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01871675 2016-07-11
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01421173 2015-11-18
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00087009 2013-03-19
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 1 Terminated
NCT00036855 2013-01-17
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated